DrugPatentWatch Database Preview
Caffeine citrate - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for caffeine citrate and what is the scope of freedom to operate?
Caffeine citrate
is the generic ingredient in two branded drugs marketed by Hikma, Aurobindo Pharma Ltd, Exela Pharma Science, Fresenius Kabi Usa, Luitpold, Micro Labs, Sagent Pharms, Sun Pharm, and Exela Pharma Scs Llc, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.There are eleven drug master file entries for caffeine citrate. Nine suppliers are listed for this compound.
Summary for caffeine citrate
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 9 |
| NDAs: | 13 |
| Drug Master File Entries: | 11 |
| Suppliers / Packagers: | 9 |
| Bulk Api Vendors: | 25 |
| Clinical Trials: | 20 |
| Patent Applications: | 227 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for caffeine citrate |
| DailyMed Link: | caffeine citrate at DailyMed |
Recent Clinical Trials for caffeine citrate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Florence | N/A |
| Ain Shams University | Phase 3 |
| Ain Shams University | Phase 1 |
Pharmacology for caffeine citrate
| Drug Class | Central Nervous System Stimulant Methylxanthine |
| Physiological Effect | Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for caffeine citrate
Synonyms for caffeine citrate
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione |
| 1,2,3-Propanetricarboxylic acid,2-hydroxy-,compounds,mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6- dione |
| 1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione 2-hydroxypropane-1,2,3-tricarboxylate |
| 2-hydroxypropane-1,2,3-tricarboxylic acid; 1,3,7-trimethylpurine-2,6-dione |
| 2-hydroxypropane-1,2,3-tricarboxylic acid;1,3,7-trimethylpurine-2,6-dione |
| 2406-91-9 |
| 69-22-7 |
| 7902AF |
| 8003-10-9 |
| AC1L1M3L |
| AKOS030254796 |
| AN-23782 |
| C-50001 |
| C8H10N4O2.C6H8O7 |
| Caffeina citrate |
| Caffeine (citrated) |
| Caffeine citrate (1:1) |
| Caffeine citrate (USP) |
| Caffeine citrated |
| Caffeine, Citrated |
| Caffeine, citrated [NF] |
| Caffeine, citrated [USAN] |
| caffeine; citro |
| CAS-69-22-7 |
| CHEMBL1200569 |
| Citrated caffein |
| Citric acid, compd. with caffeine (1:1) |
| citric acid; 1,3,7-trimethylpurine-2,6-dione |
| CTK5C9279 |
| D07603 |
| DSSTox_CID_26938 |
| DSSTox_GSID_46938 |
| DSSTox_RID_82023 |
| DTXSID5046938 |
| FT-0623368 |
| LS-121085 |
| NCGC00015208-09 |
| NCGC00015208-19 |
| NSC-63248 |
| NSC63248 |
| SCHEMBL452067 |
| Tox21_110099 |
| Tox21_110099_1 |
| U26EO4675Q |
| UNII-U26EO4675Q |
US Patents and Regulatory Information for caffeine citrate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma Scs Llc | CAFFEINE CITRATE | caffeine citrate | SOLUTION;ORAL | 077304-001 | Sep 21, 2006 | AA | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Luitpold | CAFFEINE CITRATE | caffeine citrate | SOLUTION;INTRAVENOUS | 077906-001 | May 15, 2007 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Exela Pharma Science | CAFFEINE CITRATE | caffeine citrate | SOLUTION;INTRAVENOUS | 077233-001 | Sep 21, 2006 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Sun Pharm | CAFFEINE CITRATE | caffeine citrate | SOLUTION;ORAL | 090357-001 | Sep 30, 2009 | AA | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Hikma | CAFCIT | caffeine citrate | SOLUTION;ORAL | 020793-002 | Apr 12, 2000 | AA | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Fresenius Kabi Usa | CAFFEINE CITRATE | caffeine citrate | SOLUTION;INTRAVENOUS | 077997-001 | Jul 20, 2007 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.